Abstract
Autologous hematopoietic stem cell transplantation (HSCT) has been given to persons with multiple sclerosis (MS) for over 20 years, and more than 3000 HSCTs have been done worldwide1,2. Transplant-related mortality in MS managed with HSCT, was considered a limiting factor but has decreased to < 2%2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have